📅 PUBMED DAILY TRIAGE — 2026-05-01

Window: 2026-04-30T09:00:00Z → 2026-05-01T09:00:00Z (CRDT) Topics scanned: 10 (9 watchlist + 1 sentinel) | Articles reviewed: ~95 candidates across topics | Unique articles evaluated: 12 High priority: 2 | Standard: 7 | Low/archive: 3 | Unsolicited finds: 2 Run status: SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Early Cancer Detection (liquid biopsy, ctDNA, cfDNA)

TR-2026-05-01-001 · PMID 42062528 · Preoperative ctDNA and tumor volume predict colorectal cancer recurrence after metastasis resection · 9/10 🔴

NPJ Precision Oncology, GALAXY trial, N=229. Preoperative ctDNA-to-tumor-volume integrated model stratified CRC metastasectomy patients into high/low PFS risk groups (liver: 11.4 vs 24 mo; lung: 12 mo vs not reached), outperforming either marker alone — directly actionable for perioperative surveillance decision-making.

Cardiovascular-metabolic / AI-ML Diagnostics

TR-2026-05-01-002 · PMID 42062622 · Data-driven prioritization of high-risk individuals for weight loss interventions · 10/10 🟢

Nature Medicine, N≈200,000. OBSCORE ML framework (20 features selected from thousands) predicts 18 obesity-related complications over 10 years; validated in multi-ancestry cohorts and SURMOUNT-1 tirzepatide trial participants — provides an immediately deployable evidence-based framework for GLP-1/tirzepatide treatment prioritization beyond BMI.

🟢⚪ STANDARD (5–7) — Top by Topic

Hematologic Malignancies (AML, MDS, CLL, MPN, Lymphoma)

• TR-2026-05-01-003 · PMID 42062666 · BRAF Alterations in CLL: Genomic Landscape, Co-Mutation Patterns, and Clinical Relevance · 5/10 · Genomics/Precision Medicine
• TR-2026-05-01-010 · PMID 42062652 · PET tracers for differentiating CNS lymphoma from glioblastoma · 3/10 (title-only) · Diagnostics

Early Cancer Detection (liquid biopsy, ctDNA, cfDNA)

• TR-2026-05-01-006 · PMID 42062251 · Peripheral blood cfDNA (clonoSEQ) in multiple myeloma concordant with bone marrow and clinical biomarkers · 5/10 · Diagnostics (letter format)

Precision Oncology & Genomic Medicine

• TR-2026-05-01-007 · PMID 42062763 · Carbonic Anhydrase Inhibitors in Oncology · 5/10 · Drug Development (review; CA IX/XII Phase I + ADC landscape)

Aging, Longevity, and Population Health

• TR-2026-05-01-005 · PMID 42062708 · Autophagy revealed as targetable vulnerability in senescent cells via Cell Painting profiling · 5/10 · Drug Development (in vitro cap applied; senolytics — novel mechanistic class)

Rare Diseases with High Unmet Need

• TR-2026-05-01-004 · PMID 42062395 · Sickle cell retinopathy in Africa: systematic review and meta-analysis · 7/10 🟡 · Public Health (SCD in highest-burden, underserved region)

CBC-Based Diagnostics and ML in Hematology

No high-priority finds today (best candidate scored 3/10) — 8th consecutive sparse window for this topic.

Novel Therapeutics (Immunotherapy, CAR-T, Targeted)

No high-priority finds today (best candidate 4/10). High result volume (158 raw hits) but top results were mechanistic/review; no phase 3 or first-in-human CAR-T/immunotherapy findings in window.

💡 UNSOLICITED FINDS

High-signal out-of-watchlist items:

• TR-2026-05-01-008 · PMID 42062633 · MicroRNA-mRNA Regulatory Network Associated with Cognitive Impairment in Multiple Sclerosis · 4/10 · Mol Neurobiol · N=46 · miR-146a-5p, let-7a-5p, miR-21-5p signature in MS with cognitive impairment. Outside watchlist (MS neurology). pipeline_ready=false.

• TR-2026-05-01-009 · PMID 42062698 · BTN3A2-Centered Diagnostic Risk Score in Dermatomyositis · 5/10 · Clin Rheumatol · Multi-omics, AUC 0.957 external 0.724; monocyte-T cell LGALS9-CD44/CD45 axis. Outside watchlist (rheumatology). pipeline_ready=false. Notable for high diagnostic accuracy model design.

📊 TODAY'S BREAKDOWN

By research category:

• Early Detection: 2
• Diagnostics: 4
• Genomics/Precision Medicine: 2
• Drug Development: 2
• Public Health: 1
• Prevention: 1

By evidence maturity:

• Exploratory: 8
• Validated: 4

By watchlist topic — reviewed / kept / highest score:

By source type: peer_reviewed 12 | preprint 0

Topics with zero 8+ articles this run:

• CBC-based diagnostics and ML in hematology (8th consecutive sparse window)
• Novel therapeutics: immunotherapy, CAR-T, targeted therapy
• Aging, longevity, and population health
• Hematologic malignancies
• Precision oncology
• Rare diseases

🔧 RUN NOTES

• Window expansion: Not triggered (≥5 relevant records found in standard 24h window).
• Truncation: All topics had candidate caps hit at 10; raw counts ranged from 14 (liquid biopsy) to 1,068 (sentinel). Truncation logged per topic in search_logs; most relevant candidates prioritized by CRDT date order.
• Deferred PMIDs: PMID 42056650 (ATF3 in ccRCC) reviewed and scored this run (4/10, LOW). 8 other deferred PMIDs from 2026-04-30 run not fully abstractable in this run (42056648, 42055316, 42054842, 42056639, 42056619, 42055801, 42055601, 42054834) — carried forward to 2026-05-02.
• CBC/ML hematology: 8th consecutive day with no ≥5-scoring articles. Recommend quarterly spotlight review or query broadening at 14-day mark if pattern continues.
• Novel therapeutics topic: 158 raw hits in CRDT window but top 10 were mechanistic/review articles; no phase 3 or FIH immunotherapy/CAR-T results in this window.
• Topic overlap: PMID 42062622 (OBSCORE) credited to both Cardiovascular-metabolic and AI/ML diagnostics; counted once in article list.
• Abstract retrieval: XML batch truncation at 20KB per fetch limited full abstract recovery for some records. Records scored at classification_confidence=low or medium where abstract was unavailable; title-only cap (≤3) applied to 42062652.
• Rolling 7-day trend (from state): CBC/ML consistently sparse. Novel therapeutics producing lower-quality hits in recent windows. Liquid biopsy and Cardiometabolic-ML remain the most productive topics.